Serratia marcescens nuclease is a nonspecific nuclease. Serratia marcescens nuclease has broad utility due to its potent digestive activity toward both DNA and RNA.

Glucose oxidase is used in the food and beverage industry as a preservative and stabilizer and is commonly derived from the fungus Aspergillus niger. Glucose oxidase can react with intracellular glucose and oxygen (O2) to produce hydrogen peroxide (H2O2) and gluconic acid, which can cut off the nutrition source of cancer cells and consequently inhibit their proliferation.

Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction.

Inhibitor of HSP90, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction

Pyrimidine is an endogenous metabolite. It is used to study the photoinduced ion chemistry of the halogenated pyrimidines, a class of prototype radiosensitizing molecules, and is also used to assess pyrimidine/purine asymmetry quantitatively.

FL118(10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin analog, is a potent and orally active inhibitor of Survivin. FL118 also selectively and independently inhibits three additional cancer-associated survival genes Mcl-1, XIAP, and cIAP2 in a p53 status-independent manner. FL118 displays potent antitumor activity and can be used in cancer research.

Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.

HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL.

MDL-811 (MDL811) is a potent, selective and allosteric SIRT6 activator with EC50 of 5.7 uM (activated SIRT6 deacetylation), two-fold greater activity than MDL-800 (EC50=12.3 uM, Cat# 35760).

Novel activator of SIRT6 deacetylation

p-Toluic acid (4-Methylbenzoic acid) is a methylbenzoic acid and can be used as an intermediate for the synthesis of para-aminomethylbenzoic acid (PAMBA), p-tolunitrile, etc. It also exhibits hepatotoxicological potential in humanised-liver mice.

IPN01203 is a potential first-in-class T cell‑activating fusion protein designed to selectively engage Vβ6 T cells through both the T cell receptor (TCR) and the IL‑15 receptor pathway. Rather than relying on broad, non‑specific T cell stimulation, this approach aims to enhance antitumor immunity by activating a more focused subset of the T cell repertoire.

JNJ-89862175 is an antibody-drug conjugate (ADC) directed against ENPP3, currently under development for the treatment of advanced solid tumors. This program highlights the potential of ENPP3 as a tumor-associated antigen for targeted payload delivery, expanding ADC development beyond more established surface targets in the field.

CID-078 is an orally bioavailable macrocyclic compound that binds to the RxL groove of both cyclin A and cyclin B. By engaging this conserved docking site, it blocks their interactions with multiple components of the cell cycle machinery. More specifically, this agent disrupts HP-RxL motif‑mediated protein–protein interactions within the cyclin A2/CDK2‑E2F1 and cyclin B1/CDK1‑MYT1 complexes. The resulting interference leads to cell cycle arrest and triggers apoptotic cell death in tumor cells.

HLX316 is a potential first-in-class glyco-editing biologic developed using Palleon's EAGLE platform. It is constructed by fusing a human-derived sialidase enzyme with a human anti-B7-H3 monoclonal antibody. By targeting B7-H3-expressing tumor cells, this agent drives their desialylation, thereby reversing glycosylation-mediated immune suppression within the tumor microenvironment.

AZD8359 is a STEAP2-targeting T-cell engager. STEAP2 is a highly specific prostate-associated surface antigen that is strongly expressed across all stages of prostate adenocarcinoma. Built on AstraZeneca’s TITAN platform, AZD8359 is engineered to bias activity toward CD8+ T cells. Its "2+1" antibody format favors CD8+ over CD4+ T cells, preserving tumor cell killing while reducing the risk of cytokine release syndrome and off-target toxicity.

This therapeutic candidate, known as EpiTAC, is a tissue-selective bispecific antibody developed for EGFR-driven cancers. It works by binding to ITGB6 (integrin subunit beta-6), which promotes the degradation of both wild-type and mutant forms of EGFR specifically within tumor tissues. This triggers lysosome-mediated protein breakdown, potentially expanding the reach of EGFR-targeted therapy beyond currently defined mutation-restricted patient populations.

GalNAc Lipid 1005 is a trivalent GalNAc-lipid conjugate designed for ASGPR-mediated hepatic delivery. It features a lysine-based scaffold covalently linked to three GalNAc moieties via a ​44-unit PEG spacer, anchored by a ​1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid tail.

GL6 is a trivalent GalNAc-lipid conjugate designed for ASGPR-mediated hepatic delivery. It features a lysine-based scaffold covalently linked to three GalNAc moieties via a ​36-unit PEG spacer, anchored by a ​1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid tail. This structure balances ligand accessibility (via optimized PEG length) and nanoparticle stability (via hydrophobic DSG anchoring). Compared to GL3 (TRIS scaffold, same PEG length), GL6’s simplified lysine scaffold improves manufacturability. In LDLR-deficient models, GL6 enabled ​61% liver editing (vs. 5% with standard LNPs) at 2 mg/kg, demonstrating superior ASGPR targeting. Its design minimizes ligand crowding (0.05 mol% surface density) while maximizing endosomal escape and durable gene editing.

GalNAc Lipid 1002 is a trivalent GalNAc-lipid conjugate designed for ASGPR-mediated hepatic delivery. It features a lysine-based scaffold covalently linked to three GalNAc moieties via a ​12-unit PEG spacer, anchored by a ​1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid tail.

Galnac Lipid 83 is developed by Prime Medicine Patent: WO2024220807.Galnac Lipid 83 83 is a GalNAc-conjugated lipid designed for targeted liver delivery. It features a triantennary GalNAc ligand linked via a PEG spacer (e.g., -(CH2CH2O)n-) to a branched hydrophobic tail (C18 alkyl chains). The structure includes amide/ester bonds for stability and a stereospecific configuration (R/S) to optimize ASGPR receptor binding. Integrated into lipid nanoparticles (LNPs), it enhances hepatic uptake of nucleic acids (e.g., mRNA, gene editors) by leveraging ASGPR-mediated endocytosis. Its design balances hydrophilicity (PEG) and lipophilicity (alkyl chains) for efficient encapsulation and in vivo delivery, supporting therapeutic applications in liver-specific gene editing or RNA therapies.

ISM012-042 is an orally active, selective inhibitor of PHD1 and PHD2, with IC50 values of 1.9 nM and 2.5 nM, respectively. ISM012-042 stabilizes HIF1α protein in intestinal epithelial cells, thereby activating gene transcription programs associated with mucus production, tight junction formation, anti-inflammatory mediator generation and wound healing, which fundamentally promotes mucosal barrier repair and regulates intestinal immunity. ISM012-042 can be used for the research of inflammatory bowel disease.

GSK3830052 is a novel DNMT1-selective inhibitor (IC50 = 0.11 ± 0.02 µM). In in vitro assays, compounds in this series, including GSK3830052, inhibit human DNMT1 activity selectively over DNMT3A/3B, produce robust DNA hypomethylation, and trigger transcriptional reactivation and anti‑proliferative effects in leukemia cell lines at low‑micromolar concentrations. In animal models, analogs of this series achieve significant tumor regression and survival benefit in acute myeloid leukemia xenografts with improved tolerability compared to decitabine, demonstrating dose‑dependent antitumor efficacy with reduced hematologic toxicity, although specific numeric IC₅₀/ED₅₀ values for GSK3830052 alone aren’t detailed in the open article.

FK565 is an immunoactive peptide and a nucleotide-binding oligomerization domain (Nod)-1 ligand agonist.

PSB-24040 is a potent antagonist of orphan receptor GPR17 with Ki of 83.2 nM, and pIC50 of 7.48 in calcium mobilization assays.

Novel Potent Agonist of the Orphan G Protein-Coupled Receptor GPR17 (EC 50 27.9 nM)

DL-01 formic is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.

ADAMTS-5-IN-3 (Example 37-2) is a potent inhibitor of ADAMTS-5 and ADAMTS-4 with IC50s of 8 and 12 nM, respectively. ADAMTS-5-IN-3 can be used for the research of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthrosis and/or rheumatoid arthritis.

ECI830 (CDK2-IN-37) is an orally active, ATP-competitive and highly selective CDK2 inhibitor. ECI830 shows high selectivity over other CDK family members. ECI830 can be used for the study of HR+/HER2- breast cancer and CCNE1-amplified tumors (such as ovarian cancer and lung cancer).